Leading the March
to IBD Bispecifics
Caldera Therapeutics is a clinical-stage biotechnology company developing CLD-423, a potential first-in-class bispecific antibody for inflammatory bowel disease (IBD) and other immune-mediated diseases.
CLD-423
Single-targeted IBD therapies have hit an efficacy ceiling. CLD-423 is an investigational bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways. By combining two powerful autoimmune targets in one molecule, CLD-423 aims to deliver greater efficacy than single-targeted standards of care and define the next horizon of I&I therapy.
CLD-423 is rationally designed to reduce TL1A target-based immunogenicity liabilities while optimizing efficacy, safety, pharmacokinetics, and developability.
A Phase 1 healthy volunteer trial of CLD-423 began in January 2026 and has completed dosing.
LEADERSHIP
Praveen Tipirneni, MD, MBA
Chief Executive Officer
Liangsu Wang
Chief Scientific Officer
Zhong Liu
Chief Technology Officer
Young (Danny) Oh, MD, MS
Senior Vice President,
Clinical Development
Pam Wedel
Senior Vice President,
Clinical Development Operations
Aaron Pelta
Chief Business Officer
Colm White
Chief Program Officer
CLINICAL ADVISORY BOARD
Vipul Jairath, MBChB, DPhil
Silvio Danese, MD, PhD
Peter Irving, MA, MD, FRCP
Saurabh Mehandru, MD, MBBS
Bruce Sands, MD, MS
Stefan Schreiber, MD
Praveen Tipirneni, Caldera CEO
Michael Gladstone, Atlas Venture
Aaron Royston, venBio
Xiaodi Su, LAV
Michelle Doig, Omega Funds
John Crowley, Independent Board Member
NEWS
July 29, 2026